Kanjinti is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Kanjinti is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameKanjinti
Authorized generictrastuzumab-anns
Regular generictrastuzumab-anns
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Kanjinti?
The original
–
–

Brand nameThe maker’s card

Amgen SupportPlus Co-Pay Program

Savings card from Amgen

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

Sign up on kanjinti.com 

Or call 1-866-264-2778.

In the maker’s words

“Pay as little as $0 out-of-pocket for each dose…”

From the maker’s offer on kanjinti.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Kanjinti itself, from the same company, sold without the brand name, and usually for less. For now Kanjinti is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Kanjinti is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

KANJINTI is a HER2/neu receptor antagonist indicated in adults for:

  • the treatment of HER2-overexpressing breast cancer.
  • the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

Source: the FDA label for Kanjinti (Amgen, Inc), June 23, 2026. Full label on DailyMed 

Good to know